ES2235913T3 - Utilizacion de antiinductores de receptores de gabab y de sus derivados aceptables farmaceuticamente, en la terapia de mantenimiento de la abstinencia de nicotina en pacientes dependientes de la nicotina. - Google Patents
Utilizacion de antiinductores de receptores de gabab y de sus derivados aceptables farmaceuticamente, en la terapia de mantenimiento de la abstinencia de nicotina en pacientes dependientes de la nicotina.Info
- Publication number
- ES2235913T3 ES2235913T3 ES00947901T ES00947901T ES2235913T3 ES 2235913 T3 ES2235913 T3 ES 2235913T3 ES 00947901 T ES00947901 T ES 00947901T ES 00947901 T ES00947901 T ES 00947901T ES 2235913 T3 ES2235913 T3 ES 2235913T3
- Authority
- ES
- Spain
- Prior art keywords
- nicotine
- gaba
- use according
- transcutaneous
- baclofen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 title claims abstract description 48
- 229960002715 nicotine Drugs 0.000 title claims abstract description 47
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 title claims abstract description 45
- 230000001419 dependent effect Effects 0.000 title claims abstract description 7
- 238000009115 maintenance therapy Methods 0.000 title description 2
- 239000000411 inducer Substances 0.000 claims abstract description 13
- 239000000779 smoke Substances 0.000 claims abstract description 9
- 238000011282 treatment Methods 0.000 claims abstract description 9
- 230000009467 reduction Effects 0.000 claims abstract description 7
- 238000002360 preparation method Methods 0.000 claims abstract description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 3
- KPYSYYIEGFHWSV-UHFFFAOYSA-N Baclofen Chemical compound OC(=O)CC(CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-UHFFFAOYSA-N 0.000 claims description 19
- 229960000794 baclofen Drugs 0.000 claims description 16
- 150000001875 compounds Chemical class 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 9
- 229940079593 drug Drugs 0.000 claims description 7
- 102000005962 receptors Human genes 0.000 claims description 7
- 108020003175 receptors Proteins 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 6
- 102000017934 GABA-B receptor Human genes 0.000 claims description 5
- 108060003377 GABA-B receptor Proteins 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 5
- 239000006187 pill Substances 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- -1 (methyl) phosphinic acid 3-amino-propyl phosphine Chemical compound 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- 239000000853 adhesive Substances 0.000 claims description 3
- 230000001070 adhesive effect Effects 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 150000002148 esters Chemical class 0.000 claims description 3
- 150000002170 ethers Chemical class 0.000 claims description 2
- 239000012458 free base Substances 0.000 claims description 2
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims description 2
- 238000007918 intramuscular administration Methods 0.000 claims description 2
- 239000011159 matrix material Substances 0.000 claims description 2
- 239000003405 delayed action preparation Substances 0.000 claims 1
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical group CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
- SJZRECIVHVDYJC-UHFFFAOYSA-N 4-hydroxybutyric acid Chemical group OCCCC(O)=O SJZRECIVHVDYJC-UHFFFAOYSA-N 0.000 abstract description 3
- 230000000694 effects Effects 0.000 description 15
- 230000000391 smoking effect Effects 0.000 description 13
- 239000000126 substance Substances 0.000 description 6
- 230000009471 action Effects 0.000 description 5
- 235000019504 cigarettes Nutrition 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- 241000208125 Nicotiana Species 0.000 description 4
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 4
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 206010012335 Dependence Diseases 0.000 description 3
- 206010022998 Irritability Diseases 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- QIIVUOWTHWIXFO-UHFFFAOYSA-N cgp-35348 Chemical compound CCOC(OCC)P(O)(=O)CCCN QIIVUOWTHWIXFO-UHFFFAOYSA-N 0.000 description 3
- 235000019788 craving Nutrition 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 230000001148 spastic effect Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 2
- 229930182840 (S)-nicotine Natural products 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 206010057852 Nicotine dependence Diseases 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 208000025569 Tobacco Use disease Diseases 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 238000002485 combustion reaction Methods 0.000 description 2
- 229960002069 diamorphine Drugs 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 229960002748 norepinephrine Drugs 0.000 description 2
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 230000002787 reinforcement Effects 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 208000011117 substance-related disease Diseases 0.000 description 2
- PJDFLNIOAUIZSL-UHFFFAOYSA-N vigabatrin Chemical compound C=CC(N)CCC(O)=O PJDFLNIOAUIZSL-UHFFFAOYSA-N 0.000 description 2
- MXYUKLILVYORSK-UHFFFAOYSA-N (+/-)-allo-lobeline Natural products C1CCC(CC(=O)C=2C=CC=CC=2)N(C)C1CC(O)C1=CC=CC=C1 MXYUKLILVYORSK-UHFFFAOYSA-N 0.000 description 1
- MXYUKLILVYORSK-HBMCJLEFSA-N (-)-lobeline Chemical compound C1([C@@H](O)C[C@H]2N([C@H](CCC2)CC(=O)C=2C=CC=CC=2)C)=CC=CC=C1 MXYUKLILVYORSK-HBMCJLEFSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
- OTABLIMKXCPLGL-UHFFFAOYSA-N 3-phosphanylpropan-1-amine Chemical compound NCCCP OTABLIMKXCPLGL-UHFFFAOYSA-N 0.000 description 1
- MQIWYGZSHIXQIU-UHFFFAOYSA-O 3-phosphopropylazanium Chemical compound NCCC[P+](O)=O MQIWYGZSHIXQIU-UHFFFAOYSA-O 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 206010002329 Aneurysm Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 206010003497 Asphyxia Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 108010009685 Cholinergic Receptors Proteins 0.000 description 1
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 208000003618 Intervertebral Disc Displacement Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- 206010027951 Mood swings Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029412 Nightmare Diseases 0.000 description 1
- 208000007117 Oral Ulcer Diseases 0.000 description 1
- 102000016979 Other receptors Human genes 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 229920005372 Plexiglas® Polymers 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 238000003639 Student–Newman–Keuls (SNK) method Methods 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 206010044074 Torticollis Diseases 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- 102000034337 acetylcholine receptors Human genes 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 238000013542 behavioral therapy Methods 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036471 bradycardia Effects 0.000 description 1
- 208000006218 bradycardia Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 230000005800 cardiovascular problem Effects 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 229960002896 clonidine Drugs 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 230000007278 cognition impairment Effects 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 230000007368 endocrine function Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229960002464 fluoxetine Drugs 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229930013610 lobeline Natural products 0.000 description 1
- 229960002339 lobeline Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000011418 maintenance treatment Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 229940100652 nasal gel Drugs 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000011457 non-pharmacological treatment Methods 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- NHVRIDDXGZPJTJ-UHFFFAOYSA-N skf-97,541 Chemical compound CP(O)(=O)CCCN NHVRIDDXGZPJTJ-UHFFFAOYSA-N 0.000 description 1
- 230000005586 smoking cessation Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 201000009032 substance abuse Diseases 0.000 description 1
- 231100000736 substance abuse Toxicity 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 210000002820 sympathetic nervous system Anatomy 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 238000013271 transdermal drug delivery Methods 0.000 description 1
- 230000018405 transmission of nerve impulse Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Addiction (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT1999MI001715A IT1313585B1 (it) | 1999-07-30 | 1999-07-30 | Uso di agonisti dei recettori gabab per la terapia di mantenimentodell'astinenza da nicotina in soggetti nicotino-dipendenti. |
| ITMI991715 | 1999-07-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2235913T3 true ES2235913T3 (es) | 2005-07-16 |
Family
ID=11383467
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES00947901T Expired - Lifetime ES2235913T3 (es) | 1999-07-30 | 2000-06-30 | Utilizacion de antiinductores de receptores de gabab y de sus derivados aceptables farmaceuticamente, en la terapia de mantenimiento de la abstinencia de nicotina en pacientes dependientes de la nicotina. |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP1202727B1 (fr) |
| CN (1) | CN1176650C (fr) |
| AT (1) | ATE285763T1 (fr) |
| AU (1) | AU6153400A (fr) |
| CA (1) | CA2379752C (fr) |
| DE (1) | DE60017147T2 (fr) |
| DK (1) | DK1202727T3 (fr) |
| ES (1) | ES2235913T3 (fr) |
| HK (1) | HK1046849B (fr) |
| IL (2) | IL147876A0 (fr) |
| IT (1) | IT1313585B1 (fr) |
| PL (1) | PL196334B1 (fr) |
| PT (1) | PT1202727E (fr) |
| RU (1) | RU2262352C2 (fr) |
| SI (1) | SI1202727T1 (fr) |
| WO (1) | WO2001008675A1 (fr) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1660440E (pt) | 2003-08-20 | 2012-05-15 | Xenoport Inc | Pró-fármacos de aciloxialquilcarbamato, métodos de síntese e utilização |
| EP2354120A1 (fr) | 2003-08-20 | 2011-08-10 | XenoPort, Inc. | Synthèse de promédicaments a base de carbamate d'acyloxyalkyle et leurs intermédiaires |
| US7494985B2 (en) | 2004-11-03 | 2009-02-24 | Xenoport, Inc. | Acyloxyalkyl carbamate prodrugs, methods of synthesis, and use |
| WO2006050471A2 (fr) | 2004-11-03 | 2006-05-11 | Xenoport, Inc. | Prodrogues d'acyloxyalkyl carbamate de l'acide 3-aminopropylsulfinique, et procedes de synthese et d'utilisation |
| US7585996B2 (en) | 2006-09-15 | 2009-09-08 | Xenoport, Inc. | Acyloxyalkyl carbamate prodrugs, methods of synthesis and use |
| JP4498407B2 (ja) | 2006-12-22 | 2010-07-07 | キヤノン株式会社 | プロセスカートリッジ、電子写真画像形成装置、及び、電子写真感光体ドラムユニット |
| US7868043B2 (en) | 2008-01-25 | 2011-01-11 | Xenoport, Inc. | Mesophasic forms of (3S)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use |
| TWI369202B (en) | 2008-01-25 | 2012-08-01 | Xenoport Inc | Enantiomerically resolving acyloxyalkyl thiocarbonates used in synthesizing acyloxyalkyl carbamate prodrugs |
| EP2250148B1 (fr) | 2008-01-25 | 2016-08-17 | XenoPort, Inc. | Forme cristalline de sels de calcium d'acide (3s)-aminomethyl-5-methyl-hexanoique et ses procedes d'utilisation |
| US7989641B2 (en) | 2008-08-07 | 2011-08-02 | Xenoport, Inc. | Methods of synthesizing N-hydroxysuccinimidyl carbonates |
| US8299291B2 (en) | 2008-08-07 | 2012-10-30 | Xenoport, Inc. | Methods of synthesizing 1-(acyloxy)-alkyl carbamate prodrugs |
| NZ594648A (en) | 2009-03-03 | 2013-12-20 | Xenoport Inc | Sustained release oral dosage forms of an r-baclofen prodrug |
| CA2758245A1 (fr) | 2009-04-17 | 2010-10-21 | Xenoport, Inc. | Derives d'acide gamma-aminobutyrique comme ligands des recepteurs gabab |
| WO2011081558A1 (fr) * | 2009-08-21 | 2011-07-07 | Komissarov Jury Vladimirovich | Dispositif pour fumeurs permettant de renoncer à la tabagie |
| WO2013023155A1 (fr) | 2011-08-11 | 2013-02-14 | Xenoport, Inc. | Formes cristallines anhydres et hémihydratées d'un promédicament (r)-baclofène, procédés de synthèse et procédés d'utilisation |
| AU2019249277A1 (en) * | 2018-04-06 | 2020-10-22 | Ovid Therapeutics Inc. | Use of gaboxadol in the treatment of substance use disorders |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4126684A (en) * | 1976-02-11 | 1978-11-21 | Ciba-Geigy Corporation | 4-amino-3-p-halophenylbutyric acids and their derivatives used in the control of narcotic abuse |
| US5073539A (en) * | 1990-01-22 | 1991-12-17 | Ciba-Geigy Corporation | Transdermal administration of zwitterionic drugs |
| US5760049A (en) * | 1997-02-21 | 1998-06-02 | Synapse Pharmaceuticals International, Inc. | Method for controlling tobacco use and alleviating withdrawal symptoms due to cessation of tobacco use |
| US6541520B1 (en) * | 1998-08-05 | 2003-04-01 | Brookhaven Science Associates | Treatment of addiction and addiction-related behavior |
-
1999
- 1999-07-30 IT IT1999MI001715A patent/IT1313585B1/it active
-
2000
- 2000-06-30 AU AU61534/00A patent/AU6153400A/en not_active Abandoned
- 2000-06-30 SI SI200030632T patent/SI1202727T1/xx unknown
- 2000-06-30 PL PL353373A patent/PL196334B1/pl unknown
- 2000-06-30 EP EP00947901A patent/EP1202727B1/fr not_active Expired - Lifetime
- 2000-06-30 RU RU2002105375/15A patent/RU2262352C2/ru active
- 2000-06-30 CN CNB00811031XA patent/CN1176650C/zh not_active Expired - Lifetime
- 2000-06-30 PT PT00947901T patent/PT1202727E/pt unknown
- 2000-06-30 ES ES00947901T patent/ES2235913T3/es not_active Expired - Lifetime
- 2000-06-30 IL IL14787600A patent/IL147876A0/xx active IP Right Grant
- 2000-06-30 DK DK00947901T patent/DK1202727T3/da active
- 2000-06-30 AT AT00947901T patent/ATE285763T1/de active
- 2000-06-30 CA CA002379752A patent/CA2379752C/fr not_active Expired - Fee Related
- 2000-06-30 DE DE60017147T patent/DE60017147T2/de not_active Expired - Lifetime
- 2000-06-30 WO PCT/EP2000/006120 patent/WO2001008675A1/fr active IP Right Grant
-
2002
- 2002-01-28 IL IL147876A patent/IL147876A/en unknown
- 2002-10-31 HK HK02107911.9A patent/HK1046849B/zh not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| SI1202727T1 (fr) | 2005-08-31 |
| WO2001008675A1 (fr) | 2001-02-08 |
| ITMI991715A0 (it) | 1999-07-30 |
| ITMI991715A1 (it) | 2001-01-30 |
| CN1377265A (zh) | 2002-10-30 |
| DK1202727T3 (da) | 2005-05-09 |
| EP1202727B1 (fr) | 2004-12-29 |
| PL196334B1 (pl) | 2007-12-31 |
| RU2262352C2 (ru) | 2005-10-20 |
| DE60017147D1 (de) | 2005-02-03 |
| PT1202727E (pt) | 2005-05-31 |
| CA2379752C (fr) | 2008-05-27 |
| HK1046849A1 (en) | 2003-01-30 |
| IT1313585B1 (it) | 2002-09-09 |
| ATE285763T1 (de) | 2005-01-15 |
| PL353373A1 (en) | 2003-11-17 |
| CA2379752A1 (fr) | 2001-02-08 |
| IL147876A (en) | 2007-06-17 |
| AU6153400A (en) | 2001-02-19 |
| EP1202727A1 (fr) | 2002-05-08 |
| IL147876A0 (en) | 2002-08-14 |
| HK1046849B (zh) | 2005-07-15 |
| CN1176650C (zh) | 2004-11-24 |
| DE60017147T2 (de) | 2006-01-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2235913T3 (es) | Utilizacion de antiinductores de receptores de gabab y de sus derivados aceptables farmaceuticamente, en la terapia de mantenimiento de la abstinencia de nicotina en pacientes dependientes de la nicotina. | |
| US6893654B2 (en) | Two-stage transmucosal medicine delivery system for symptom relief | |
| RU2535046C2 (ru) | Композиции для лечения злоупотребления веществами, вызывающими болезненное пристрастие, и улучшения поведения, связанного со злоупотреблениями | |
| KR100301547B1 (ko) | 니코틴의존증치료용약학조성물 | |
| PT1642578E (pt) | Composição de sal de fentanilo para administração nasal | |
| Caprioli et al. | Environmental modulation of cocaine self-administration in the rat | |
| JP4173538B2 (ja) | 痛みの管理及び解毒のためのケタミンの点鼻及び点眼投与 | |
| RU2445971C2 (ru) | Водный экстракт листьев табака и его применение при лечении зависимости | |
| US6630449B2 (en) | Method for reducing the effect of nicotine addiction and dependancy | |
| Maseeh et al. | A review of smoking cessation interventions | |
| CA2494743A1 (fr) | Niacine (acide nicotinique) utilisee comme supplementation orale dans le traitement de sevrage de programmes de desaccoutumance au tabac | |
| BRPI1015515A2 (pt) | Método para diminuir a vontade de fumar, que não produz irritação | |
| US20090156561A1 (en) | Use of Cholinesterase Inhibitors In Smoking Cessation | |
| Milhorn et al. | Opioids | |
| EA012460B1 (ru) | Лекарство и способ для снижения потребления алкоголя и/или табака | |
| Roopchandani et al. | Smoking cessation aids | |
| Klous et al. | Pharmaceutical heroin for medical co-prescription to opioid dependent patients in methadone maintenance treatment | |
| EA004718B1 (ru) | Способ сокращения или прекращения курения |